Type 2 Diabetes Ups Risk of Renal Cancer in Women, but Not Men

Share this content:
Type 2 Diabetes Ups Risk of Renal Cancer in Women, but Not Men
Type 2 Diabetes Ups Risk of Renal Cancer in Women, but Not Men

TUESDAY, May 8, 2018 (HealthDay News) -- Type 2 diabetes is independently associated with a greater risk of renal cell carcinoma (RCC) in women, but not in men, according to a study published online April 20 in Diabetes Care.

Rebecca E. Graff, Sc.D., from Harvard University in Boston, and colleagues used data from 117,570 women participating in the Nurses' Health Study (NHS; 1976 to 2014) and 48,866 men participating in the Health Professionals Follow-up Study (HPFS; 1986-2014) in order to assess whether type 2 diabetes is associated with RCC.

The researchers found that among NHS participants there were 418 RCC cases, including 120 fatal cases, and among HPFS participants there were 302 RCC cases, including 87 fatal cases. There was a significantly increased risk of RCC among women with type 2 diabetes versus women without type 2 diabetes (multivariable hazard ratio [HR], 1.53; 95 percent confidence interval [CI], 1.14 to 2.04). This association was stronger for no more than five years' duration of type 2 diabetes (HR, 2.15; 95 percent CI, 1.44 to 3.23) versus more than five years' duration (HR 1.22; 95 percent CI, 0.84 to 1.78) (P = 0.03). However, there was no association between diabetes and RCC among men (HR, 0.89; 95 percent CI, 0.56 to 1.41).

"Additional studies in populations with adequate confounder information are needed to confirm our findings and to further explore possible sex differences in the association between type 2 diabetes and RCC," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths